Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.7408
-0.0224-2.94%
Post-market: 0.74080.00000.00%19:44 EDT
Volume:720.67K
Turnover:540.73K
Market Cap:62.57M
PE:-0.25
High:0.7750
Open:0.7600
Low:0.7302
Close:0.7632
Loading ...

BRIEF-Sutro Biopharma FY Revenue USD 62.043 Million

Reuters
·
14 Mar

Sutro Biopharma Inc - Cash Payments Associated With Restructuring Are Estimated to Be $40 to $45 Mln

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Inc - Jane Chung, President and COO, to Succeed BILL Newell as CEO and Board Director

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Inc - Will Reduce Its Organizational Headcount by Nearly 50 Percent

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Inc - Intends to Exit Its Internal Gmp Manufacturing Facility by Year-End

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of Its Next-Generation ADC Pipeline

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Inc: Cash Runway Expected Into at Least Q4 2026

THOMSON REUTERS
·
14 Mar

Press Release: Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Dow Jones
·
14 Mar

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

GlobeNewswire
·
14 Mar

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
12 Mar

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
04 Mar

We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Simply Wall St.
·
22 Jan

Sutro Biopharma (STRO) Gets a Buy from Bank of America Securities

TIPRANKS
·
16 Jan

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
08 Jan

Sutro Biopharma and Boehringer Ingelheim Bioxcellence™ Collaboration: Established First-in-Class Cell-Free Capabilities at Commercial Scale

THOMSON REUTERS
·
07 Jan

Sutro Biopharma, Boehringer announce application of Sutro’s technology

TIPRANKS
·
07 Jan

Great week for Sutro Biopharma, Inc. (NASDAQ:STRO) institutional investors after losing 42% over the previous year

Simply Wall St.
·
07 Jan